News coverage about Quotient (NASDAQ:QTNT) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quotient earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.804703137293 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Quotient (NASDAQ QTNT) traded up $0.04 during midday trading on Friday, reaching $4.12. 485,538 shares of the company were exchanged, compared to its average volume of 277,686. The firm has a market cap of $185.88, a price-to-earnings ratio of -1.43 and a beta of 1.40. The company has a debt-to-equity ratio of -5.17, a quick ratio of 0.86 and a current ratio of 1.36. Quotient has a 12-month low of $3.22 and a 12-month high of $7.74.
Several brokerages have recently issued reports on QTNT. Zacks Investment Research raised shares of Quotient from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Jefferies Group reduced their target price on shares of Quotient from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, November 1st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $12.00 target price on shares of Quotient in a research note on Wednesday, November 1st.
In related news, insider D J. Paul E. Cowan sold 45,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $4.55, for a total value of $204,750.00. Following the completion of the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $121,330.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider D J. Paul E. Cowan sold 30,197 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $4.92, for a total transaction of $148,569.24. Following the completion of the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at $131,196.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 175,197 shares of company stock valued at $817,319. Company insiders own 29.00% of the company’s stock.
WARNING: This piece was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-quotient-qtnt-stock-price.html.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.